AU758235B2 - Vaccine for Pseudomonas aeruginosa - Google Patents

Vaccine for Pseudomonas aeruginosa Download PDF

Info

Publication number
AU758235B2
AU758235B2 AU35910/99A AU3591099A AU758235B2 AU 758235 B2 AU758235 B2 AU 758235B2 AU 35910/99 A AU35910/99 A AU 35910/99A AU 3591099 A AU3591099 A AU 3591099A AU 758235 B2 AU758235 B2 AU 758235B2
Authority
AU
Australia
Prior art keywords
peptide
pak
pao
seq
antiserum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU35910/99A
Other languages
English (en)
Other versions
AU3591099A (en
Inventor
Paul J Cachia
Robert S. Hodges
Randall T. Irvin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Publication of AU3591099A publication Critical patent/AU3591099A/en
Application granted granted Critical
Publication of AU758235B2 publication Critical patent/AU758235B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU35910/99A 1998-05-06 1999-05-06 Vaccine for Pseudomonas aeruginosa Ceased AU758235B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8444498P 1998-05-06 1998-05-06
US60/084444 1998-05-06
PCT/CA1999/000366 WO1999057142A2 (en) 1998-05-06 1999-05-06 Vaccine for $i(pseudomonas aeruginosa)

Publications (2)

Publication Number Publication Date
AU3591099A AU3591099A (en) 1999-11-23
AU758235B2 true AU758235B2 (en) 2003-03-20

Family

ID=22185008

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35910/99A Ceased AU758235B2 (en) 1998-05-06 1999-05-06 Vaccine for Pseudomonas aeruginosa

Country Status (6)

Country Link
US (2) US6541007B1 (enExample)
EP (1) EP1082342A2 (enExample)
JP (1) JP2002513802A (enExample)
AU (1) AU758235B2 (enExample)
CA (1) CA2328495A1 (enExample)
WO (1) WO1999057142A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057142A2 (en) * 1998-05-06 1999-11-11 The Governors Of The University Of Alberta Vaccine for $i(pseudomonas aeruginosa)
US20030228324A1 (en) * 1999-05-06 2003-12-11 Malcolm Andrew J. Peptide compositions and methods of producing and using same
WO2002060935A2 (en) * 2000-12-21 2002-08-08 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences
WO2003042240A2 (en) * 2001-11-13 2003-05-22 Shire Biochem Inc. Polypeptides of pseudomonas aeruginosa
EP1790659B1 (en) 2001-11-13 2013-07-31 ID Biomedical Corporation Polypeptides of pseudomonas aeruginosa
US20090208535A1 (en) * 2004-06-28 2009-08-20 Proteome Systems Intellectual Property Pty Ltd Novel Methods of Diagnosis of Treatment of P. Aeruginosa Infection and Reagents Therefor
AU2005294436A1 (en) 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
US7976851B2 (en) * 2005-07-22 2011-07-12 The Regents Of The University Of Colorado, A Body Corporate Non-toxic biofilm inhibitor
WO2007093177A2 (en) 2006-02-14 2007-08-23 Vladimir Berezin Metallothionein-derived peptide fragments
RU2553557C2 (ru) * 2013-07-08 2015-06-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" Способ изготовления вакцины, ассоциированной против псевдомоноза и вирусной геморрагической болезни кроликов
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5223604A (en) * 1991-06-25 1993-06-29 S.P.I. Synthetic Peptides Incorporated Pseudomonas exoenzyme s peptide composition and method
WO1999057142A2 (en) * 1998-05-06 1999-11-11 The Governors Of The University Of Alberta Vaccine for $i(pseudomonas aeruginosa)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CACHIA P J ET AL, J. OF PEPTIDE RES. VOL.52 NO.4 PGS 289-299 *

Also Published As

Publication number Publication date
WO1999057142A2 (en) 1999-11-11
US20030211114A1 (en) 2003-11-13
CA2328495A1 (en) 1999-11-11
WO1999057142A3 (en) 2000-02-03
JP2002513802A (ja) 2002-05-14
AU3591099A (en) 1999-11-23
EP1082342A2 (en) 2001-03-14
US6541007B1 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
JP4109939B2 (ja) 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）のプロテイナーゼＫ抵抗性表面蛋白質
US20030021795A1 (en) Use of coiled-coil structural scaffold to generate structure-specific peptides
AU758235B2 (en) Vaccine for Pseudomonas aeruginosa
Forest et al. Assembly and antigenicity of the Neisseria gonorrhoeae pilus mapped with antibodies
US5223604A (en) Pseudomonas exoenzyme s peptide composition and method
US6004562A (en) Outer membrane protein B1 of Moraxella catarrhalis
Cachia et al. The use of synthetic peptides in the design of a consensus sequence vaccine for Pseudomonas aeruginosa
US20030228324A1 (en) Peptide compositions and methods of producing and using same
EP0567470B1 (en) Pseudomonas peptide composition and method for producing the same
JP4081140B2 (ja) 非耐熱性エンテロトキシンとコレラトキシンｂサブユニットの雑種分子
JP2762310B2 (ja) ストレプトコッカルｍプロテイン由来の合成ペプタイド及び当該ペプタイドから調製されたワクチン
JP2002527041A (ja) 淋菌（Ｎｅｉｓｓｅｒｉａｇｏｎｏｒｒｈｏｅａｅ）または髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）に対する組換えピリンを含有するワクチン
US7189405B1 (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
Olson et al. Identification of functional epitopes of Pseudomonas aeruginosa exotoxin A using synthetic peptides and subclone products
CA2516661C (en) M. haemolytica outer membrane protein plpe as a vaccine or vaccine component against shipping fever
WO1994008013A9 (en) Pilin variants and uses thereof
Chong et al. Immunogenicity of synthetic peptides of Haemophilus influenzae type b outer membrane protein P1
AU2003299131B2 (en) Therapeutic USPA1-derived peptides
EP1688428A1 (en) Method of antigen incorporation into neisseria bacterial outer membrane vesicles and resulting vaccine formulations
van Doom et al. Characterization and detection of the 40 kDa fimbrial subunit of Bacteroides fragilis BE1
CN100387718C (zh) 抗蛋白酶k降解的脑膜炎奈瑟氏球菌表面蛋白
CN101638433A (zh) 保守淋球菌表位的拟肽及应用它们的方法和组合物
HK1141034B (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
HK1076475B (en) Therapeutic uspa1-derived peptides

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)